Get the App
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Monday, May 27, 2024

 ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2024 ,inter alia, to consider and approve 1. The Audited financial results of the Company for the quarter and year ended March 31, 2024. 2. To recommend Dividend, if any, on the equity shares of the Company for the financial year 2023-24. We also inform you that the 'Trading Window' remains closed for all Designated Persons, from March 16, 2024 to May 29, 2024 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015. We request you to please take the same on record.
15-05-2024

Covishield off shelves for 2 years in India, AstraZeneca withdraws globally

 In India, Covishield is manufactured by the Serum Institute of India (SII) under a licensing agreement with AstraZeneca. SII, one of the world's leading vaccine producers, ceased Covishield production in December 2021 due to low demand.
08-05-2024
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 We are enclosing herewith the certificate dated May 2, 2024 issued by Integrated Registry Management Services Private Limited, RTA of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.
03-05-2024

Bharat Biotech Asserts Covaxin's Safety Amid AstraZeneca's Rare Side-Effects Admission

 Bharat Biotech asserts Covaxin's safety after AstraZeneca's rare side-effects admission, stating it was developed with a focus on safety and efficacy.
02-05-2024
Bigul

Effect and side effect: the story of AstraZeneca's COVID vaccine
02-05-2024

'Sympathy goes out to anyone who lost loved ones,' says AstraZeneca on Covishield row

 The admission came a day after the pharma giant admitted in a UK court that its COVID-19 vaccine sold globally as Covishield and Vaxzevria may cause Thrombocytopenia Syndrome (TTS) in "very rare cases".
01-05-2024
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

 Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyASTRAZENECA PHARMA INDIA LTD. 2CIN NO.L24231KA1979PLC003563 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY 000 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Manasa R Designation: Company Secretary EmailId: manasa.r1@astrazeneca.com Name of the Chief Financial Officer: Bhavana Agrawal Designation: Chief Financial Officer and Director EmailId: bhavana.agrawal@astrazeneca.com Date: 19/04/2024 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
19-04-2024
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Certificate Under Regulation 40(10) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

 As required under Regulation 49(10) of SEBI (LODR) Regulations, 2015, we furnish herewith a certificate issued by the Practising Company Secretary with regard to transfer of securities effected during the year ended March 31, 2024.
16-04-2024
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Certificate Under Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

 This is to certify that Integrated Registry Management Services Private Limited, are the Company''s RTA and that all activities are in relation to the share transfer are maintained by them. We are also attaching the certificate received from our RTA.
12-04-2024
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 We are enclosing herewith the Certificate dated April 5, 2024 issued by the RTA of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.
12-04-2024
Next Page
Close

Let's Open Free Demat Account